Kobayashi Pharmaceuticals Chemical Division Vows to Transform Corporate Climate
Kobayashi Pharmaceutical Co., a drug and supplement maker based in Osaka, Japan, is implementing strategies to reform its corporate culture following the beni koji scandal that came to light early last year. The health hazard was caused by supplements containing "beni koji" red yeast rice ingredients, which became public knowledge during a period of strong net profit growth for the company.
At the heart of the issue is a strong tendency among employees to depend on top management, a problem that was highlighted during the period of growth. Chairman Yoshihito Ota, who was invited from outside the company to take his position, has emphasized the need to change this culture where employees tended to depend on leadership rather than assert themselves.
To address this issue, Kobayashi Pharmaceutical Co. is undertaking leadership and governance reforms. The company has replaced its president twice and appointed an external chairman to reduce the dominance of the founding family, whose control (about 30% equity stake) was identified as a root cause of the scandal and a barrier to internal reform efforts. These leadership changes are crucial parts of restoring public trust and moving beyond the troubled legacy associated with the beni koji health hazard.
The reforms also aim to foster a more autonomous and accountable workforce. For many employees at Kobayashi Pharmaceutical Co., it was easier to work by depending on someone rather than asserting themselves during the period of strong growth. By encouraging independent action, the company hopes to create a more dynamic and innovative work environment.
The broader context includes not only cultural dependency but also systemic failures such as deceptive practices and inadequate quality tests uncovered in the post-scandal investigations. The regulatory environment and pricing pressures in Japan’s pharmaceutical industry have contributed to corporate complacency and underinvestment in management systems. As such, Kobayashi’s reforms must address both cultural and operational weaknesses to ensure compliance and quality assurance going forward.
Yoshihito Ota took office in March 2021, and Kobayashi Pharmaceutical Co. achieved net profit growth for over 20 years from its stock market listing in 1999. The net profit growth was mainly led by top executives from the founding family during the period of strong growth.
In summary, Kobayashi’s strategies to reform its dependent corporate culture after the beni koji scandal involve actively reshaping corporate culture to reduce employee dependency on top management and encourage independent action, overhauling governance by appointing external executives and diluting the founding family's control, addressing broader systemic issues revealed by the scandal, including strengthening quality controls and management practices in a challenging regulatory and economic environment, and ensuring compliance and quality assurance going forward.
- In an effort to promote a more autonomous workforce and foster innovation, Kobayashi Pharmaceutical Co. is working on reforming their corporate culture, which previously encouraged employees to depend on top management.
- The financial industry will be keen to observe the progress of Kobayashi Pharmaceutical Co.'s business strategies, as their reforms aim to address cultural and operational weaknesses, ensuring compliance and quality assurance for future success.
